Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Dowling

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|January 20, 2015
Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trialOlivia May Dean, Michael Maes, Melanie Ashton, et al.
CNS Drugs|September 17, 2015
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled StudyJerome Sarris, Georgina Oliver, David A Camfield, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 9, 2014
Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depressionOlivia M Dean, Alyna Turner, Gin S Malhi, et al.
BMC Medicine|January 26, 2019
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
BMC Medicine|February 18, 2019
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
The Australian and New Zealand Journal of Psychiatry|June 6, 2017
Adjunctive minocycline treatment for major depressive disorder: A proof of concept trialOlivia M Dean, Buranee Kanchanatawan, Melanie Ashton, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|May 23, 2019
Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trialBianca E Kavanagh, Lana J Williams, Michael Berk, et al.
CNS Spectrums|June 24, 2021
Treatment of refractory obsessive-compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot studyJerome Sarris, Gerard J Byrne, Georgina Oliver, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 19, 2022
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trialJerome Sarris, Gerard Byrne, David Castle, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|January 20, 2015
Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trialOlivia May Dean, Michael Maes, Melanie Ashton, et al.
CNS Drugs|September 17, 2015
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled StudyJerome Sarris, Georgina Oliver, David A Camfield, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|October 9, 2014
Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depressionOlivia M Dean, Alyna Turner, Gin S Malhi, et al.
BMC Medicine|January 26, 2019
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
BMC Medicine|February 18, 2019
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.
The Australian and New Zealand Journal of Psychiatry|June 6, 2017
Adjunctive minocycline treatment for major depressive disorder: A proof of concept trialOlivia M Dean, Buranee Kanchanatawan, Melanie Ashton, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|May 23, 2019
Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trialBianca E Kavanagh, Lana J Williams, Michael Berk, et al.
CNS Spectrums|June 24, 2021
Treatment of refractory obsessive-compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot studyJerome Sarris, Gerard J Byrne, Georgina Oliver, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 19, 2022
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trialJerome Sarris, Gerard Byrne, David Castle, et al.
Pageof 2